We are live on ! Find out more
AKBA icon

Akebia Therapeutics
AKBA

75 hedge funds and large institutions have $30.9M invested in Akebia Therapeutics in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 32 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

926% more call options, than puts

Call options by funds: $400K | Put options by funds: $39K

87% more capital invested

Capital invested by funds: $16.5M → $30.9M (+$14.4M)

0.03% more ownership

Funds ownership: 28.39% → 28.41% (+0.03%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

17% less funds holding

Funds holding: 90 → 75 (-15)

61% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 23

78% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 32

Holders
75
Holders Change
-15
Holders Change %
-16.67%
% of All Funds
1.21%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
9
Increased
7
Reduced
32
Closed
23
Calls
$400K
Puts
$39K
Net Calls
+$361K
Net Calls Change
+$116K

Top Buyers

Rank Fund Capital Flow
1
AIM
Alerce Investment Management
Illinois
+$3.27M
2
Jane Street
Jane Street
New York
+$161K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$20.2K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$19K
5
TSS
Two Sigma Securities
New York
+$18.1K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$670K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$609K
3
BlackRock
BlackRock
New York
-$428K
4
Federated Hermes
Federated Hermes
Pennsylvania
-$245K
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$199K
Name Holding Trade Value Shares
Change 		Change in
Stake
Tudor Investment Corp
26
Tudor Investment Corp
Connecticut
$82K -$1.39K -4,434 -3%
Bank of America
27
Bank of America
North Carolina
$77.2K -$46.4K -147,942 -53%
Charles Schwab
28
Charles Schwab
California
$76.4K – – –
Connor, Clark & Lunn Investment Management (CC&L)
29
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$69.3K -$122K -390,049 -76%
E
30
Ergoteles
New York
$56.3K -$21.2K -67,716 -41%
TSS
31
Two Sigma Securities
New York
$48.3K +$18.1K +57,634 +221%
Franklin Resources
32
Franklin Resources
California
$47.6K – – –
Bank of New York Mellon
33
Bank of New York Mellon
New York
$41.4K – – –
Mackenzie Financial
34
Mackenzie Financial
Ontario, Canada
$39.3K – – –
OCM
35
Orchard Capital Management
Illinois
$38.6K -$58K -185,000 -73%
UBS Group
36
UBS Group
Switzerland
$34.1K -$22.9K -73,206 -55%
HighTower Advisors
37
HighTower Advisors
Illinois
$34K +$2.32K +7,401 +14%
EDRH
38
Edmond de Rothschild Holding
Switzerland
$28.9K – – –
CAMG
39
CWA Asset Management Group
Florida
$16.7K – – –
FPCM
40
Financial Partners Capital Management
New York
$15.9K – – –
JJBC
41
James J. Burns & Company
New York
$15K – – –
Victory Capital Management
42
Victory Capital Management
Texas
$11.4K -$3 -8 -0%
WE
43
Wealth Effects
Massachusetts
$10.6K – – –
TRCT
44
Tower Research Capital (TRC)
New York
$10K -$6.46K -20,612 -54%
Goldman Sachs
45
Goldman Sachs
New York
$8.84K -$141K -448,482 -97%
Qube Research & Technologies (QRT)
46
Qube Research & Technologies (QRT)
United Kingdom
$8.57K -$61.1K -194,900 -93%
SS
47
Sunbelt Securities
Texas
$8.08K – – –
OBWG
48
Onyx Bridge Wealth Group
New York
$8.03K – – –
Wells Fargo
49
Wells Fargo
California
$7.78K -$105 -335 -2%
Citadel Advisors
50
Citadel Advisors
Florida
$7.73K -$90.2K -287,777 -96%
1
2
3 4

AKBA Hedge Fund Activity: Q4 2022 in Review

75 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q4 2022, worth a combined $30.9M — up 87% from $16.5M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of AKBA and 9 opened new positions — a net loss of 14 holders — while 32 trimmed existing stakes and 7 added.

The largest buyer was Alerce Investment Management, adding an estimated $3.27M. The largest seller was Millennium Management, cutting an estimated $670K.

  • 75 institutional investors held Akebia Therapeutics (AKBA) as of Q4 2022, down from 90 in Q3 2022.
  • Funds reported $30.9M of Akebia Therapeutics stock for Q4 2022, up 87% quarter-over-quarter.
  • 9 funds opened new Akebia Therapeutics positions in Q4 2022 and 23 closed out, a net change of -14 holders.
  • The largest Akebia Therapeutics buyer in Q4 2022 was Alerce Investment Management, an estimated $3.27M added.
  • The largest Akebia Therapeutics seller in Q4 2022 was Millennium Management, an estimated $670K sold.

Based on aggregated 13F filings for Q4 2022.